1-3 of 3
immunoglobulin deposition disease
Close
Sort by
Journal Articles

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

Efstathios Kastritis, Ioanna Dialoupi, Maria Gavriatopoulou, Maria Roussou, Nikolaos Kanellias, Despina Fotiou, Ioannis Ntanasis-Stathopoulos, Elektra Papadopoulou, Dimitrios C. Ziogas, Kimon Stamatelopoulos, Efstathios Manios, Argyrios Ntalianis, Evangelos Eleutherakis-Papaiakovou, Asimina Papanikolaou, Magdalini Migkou, Aristea-Maria Papanota, Harikleia Gakiopoulou, Erasmia Psimenou, Maria Irini Tselegkidi, Ourania Tsitsilonis, Ioannis Kostopoulos, Evangelos Terpos, Meletios A. Dimopoulos
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3002–3009.
https://doi.org/10.1182/bloodadvances.2019000147
Published: 2019
Includes: Supplemental data
Journal Articles

Epidemiology of AL amyloidosis: a real-world study using US claims data

Tiffany P. Quock, Tingjian Yan, Eunice Chang, Spencer Guthrie, Michael S. Broder
Journal: Blood Advances
Blood Adv (2018) 2 (10): 1046–1053.
https://doi.org/10.1182/bloodadvances.2018016402
Published: 2018
Includes: Supplemental data
Journal Articles

Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation

Clinical Trials & Observations
M Hasib Sidiqi, Mohammed A. Aljama, Eli Muchtar, Francis K. Buadi, Rahma Warsame, Martha Q. Lacy, Angela Dispenzieri, David Dingli, Nelson Leung, Wilson I. Gonsalves, Shaji K. Kumar, Prashant Kapoor, Taxiarchis V. Kourelis, William J. Hogan, Morie A. Gertz
Journal: Blood Advances
Blood Adv (2018) 2 (7): 769–776.
https://doi.org/10.1182/bloodadvances.2018016782
Published: 2018
Includes: Supplemental data